Insights
Search Results
Client Highlights
4.14.26
Firm Advises Getlabs on Acquisition by Function
On April 8, 2026, Function Health announced it has acquired Getlabs, a leading mobile healthcare platform that brings licensed specialists directly to one's location. The acquisition allows for the continuation of Getlab’s nationwide network of providers, health systems, and partners, while advancing Function's broader commitment to making healthcare more accessible by building experiences around member needs. Wilson Sonsini Goodrich & Rosati advised Getlabs on the transaction.
Client Highlights
2.05.26
Wilson Sonsini Advises Fair Square Medicare on Acquisition by Senior Market Sales
On January 30, 2026, Senior Market Sales®(SMS), one of the industry’s premier insurance marketing organizations (IMOs), announced that it has acquired Fair Square Medicare, a technology-driven health care platform designed to simplify the Medicare experience for seniors. This strategic acquisition enhances SMS’ suite of digital tools and reinforces its commitment to providing guidance to seniors as they navigate Medicare coverage. Wilson Sonsini Goodrich & Rosati advised Fair Square on the transaction.
Client Highlights
8.28.25
Firm Advises SparkMeter on Platform Acquisition by Honeywell
On August 20, 2025, Honeywell announced the expansion of its Smart Energy portfolio with the tuck-in acquisition of three utility platforms from SparkMeter, Inc., a provider of leading grid management solutions for utilities. The acquisition includes intellectual property and certain related assets from SparkMeter. Wilson Sonsini Goodrich & Rosati advised SparkMeter on the transaction.
Client Highlights
1.06.25
Wilson Sonsini Advises Clear Future on Purchase of FC2 Female Condom
On December 31, 2024, Veru Inc., a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, announced that it has sold its FC2 Female Condom® (Internal Condom) business to clients managed by Riva Ridge Capital Management LP, a New York City-based investment management firm, as well as other co-investors subject to adjustment as set forth in the purchase agreement. Wilson Sonsini Goodrich & Rosati advised Clear Future, Inc. on the transaction.
Client Highlights
11.30.23
Firm Advises SparkMeter on Honeywell Smart Energy Investment and Partnership
On November 29, 2023, SparkMeter, a provider of grid management services, equipment, and software solutions that increase access to reliable electricity in underserved communities across Africa, Asia, and the Americas, announced a strategic $5 million investment and global partnership with Honeywell Smart Energy, one of the largest utility digital solution providers in the world. Wilson Sonsini Goodrich & Rosati advised SparkMeter on the transaction.
Client Highlights
6.21.23
Wilson Sonsini Advises Delve Bio on Licensing from UCSF, Launch, and $35 Million Series A Financing
On June 20, 2023, Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, debuted with $35 million in Series A financing led by Perceptive Xontogeny Venture Fund II (PXV Fund II) – and joined by Section 32 and GV. The funds will be used to commercialize the company’s mNGS-based infectious disease test – which was developed by world-renowned infectious disease experts at the University of California San Francisco (UCSF) Center for Next-Gen Precision Diagnostics – and advance a pipeline of next-generation tests. Delve Bio was started in connection with UCSF through its engagement and opportunity development team in Innovation Ventures’ Office of Technology Management and Advancement (OTMA), which leads licensing, start-up, and business development efforts on behalf of the university. The company holds an exclusive in-license from UCSF for the development and commercialization of its mNGS diagnostic platform, including its clinically validated mNGS test for cerebrospinal fluid that has been widely used by clinicians to solve complex cases of meningitis and encephalitis.
Press Releases
9.28.22
Rob Parr Rejoins Wilson Sonsini in Boston as the Firm Continues to Expand its Technology Transactions Department
Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Rob Parr has rejoined the firm’s technology transactions department as a partner in the Boston office. His return reflects Wilson Sonsini’s continued growth in Boston and the ongoing demand for tech-driven deal experience.